Company Profile for OMRIX Biopharmaceuticals, Inc.OMRIX Biopharmaceuticals, Inc. discovers, develops and manufactures innovative, novel technologies to provide safer and more effective options to patients with unmet medical needs, particularly in the areas of biosurgical and passive immunotherapy products. We are utilizing our proprietary protein purification technology, innovative development capabilities, and manufacturing know-how to develop these product lines, often through collaborations with companies whose marketing and sales expertise are a complement to our own areas of specialty. Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis hemostasis /he·mo·sta·sis/ (he?mo-sta´sis) (he-mos´tah-sis) 1. the arrest of bleeding by the physiological properties of vasoconstriction and coagulation or by surgical means. 2. , and other surgical applications. We compete in the active biosurgical hemostats hemostats Surgery A hand-held surgical instrument with flattened opposing surfaces used to occlude blood vessels for hemostasis market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia vac·cin·i·a n. 1. See cowpox. 2. An infection induced in humans by inoculation with the vaccinia virus in order to confer resistance to smallpox; it is usually limited to the site of inoculation. immunoglobulin, or VIG VIG Vaccine Immune Globulin VIG Video Interface Group (Navy) VIG Vision Interface Group (Massachusetts Institute of Technology) VIG Video Gateway VIG Vpn Internet Gateway , to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG IVIG Intravenous immunoglobulin, see there , an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic immune globulin (HBIG HBIg Hepatitis B immunoglobulin A 3-5 ml preparation of antibodies against HBV, derived from donor pools and administered at the time of presumed exposure to HBV. See HBV. ), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.
Company: OMRIX Biopharmaceuticals, Inc.
Headquarters Address: 630 Fifth Avenue, Suite 2265
New York, NY 10111
Main Telephone: (212) 887-6500
Website: www.omrix.com
Ticker: OMRI(NASDAQ)
Type of Organization: Public
Industry: Health: Medical Devices
Earnings Release Dates: 1st Quarter: May 10, 2006
2nd Quarter: August 8, 2006
Key Executives: CEO: Robert Taub
CFO: Michael Burshtine
Investor Relations
Contact: Francesca DeMartino
Phone: (212) 887-6510
Email: francesca.demartino@omrix.com
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion